A5101782331- Asthma and respiratory diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Vitamin K Research Studies
- Liver Disease and Transplantation
- Biosimilars and Bioanalytical Methods
- Delphi Technique in Research
- Drug-Induced Adverse Reactions
- Respiratory and Cough-Related Research
- Cardiac, Anesthesia and Surgical Outcomes
- Pharmacovigilance and Adverse Drug Reactions
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Huazhong University of Science and Technology
2024-2025
Tongji Hospital
2018-2025
Riociguat is a novel soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension (PAH). Despite its widespread use, there has been lack large-scale studies assessing adverse events (AEs) associated with this medication. This study aimed to evaluate AEs related by analyzing data from FDA Adverse Event Reporting System (FAERS) Q4 2013 Q1 2024. A total 12,149 AE reports were analyzed using four different disproportionality signal detection methodologies...
Objectives Diabetes is a common comorbidity in COPD population. This study aimed to explore the impacts of T2DM on clinical characteristics and outcomes patients with exacerbation COPD, as well develop specified prognostic model for these patients. Methods AECOPD were enrolled from prospective, noninterventional, multicenter cohort study. Propensity score matching 1:2 ratio was performed compare prognosis between without T2DM. Predictors short-term mortality determined by logistic regression...
Details of patients hospitalized for asthma exacerbation in mainland China are lacking. To improve disease control and reduce economic burden, a large sample survey among this patient population is indispensable. This study aimed to investigate the clinical characteristics outcomes such patients.A retrospective was conducted on 29 hospitals regions during period 2013 2014. Demographic features, pre-admission conditions, details, were summarized. Risk factors severity analyzed.There 3,240...
Tezepelumab is the first asthma biologic approved by FDA that not restricted biomarker phenotypes. To date, there have been no studies reporting adverse events (AEs) associated with real-world use of tezepelumab.
Objective: To understand the seasonal distribution of patient hospitalization due to asthma exacerbation in 7 geographic areas China. Methods: This was a retrospective study which involved patients hospitalized for 29 hospitals throughout mainland China (northeast, north, central, east, south, northwest and southwest). The numbers asthmatic total inpatients respiratory department each hospital were recorded. monthly ratio every area calculated compared. Results: During period, 6 480 admitted...